In the spring of 2026, thirty-five oncologists, researchers, and patient advocates from six continents formalized a shared conviction: that the cancer research most essential to patients — not to markets — is quietly being eroded. Coordinated by the EORTC and announced in The Lancet Oncology, their new commission exists to name the forces threatening independent academic trials and to propose the structural changes needed to preserve them. At stake is not merely a funding dispute, but the question of whose lives the evidence of medicine is built around.
Global Coalition Launches Lancet Oncology Commission to Champion Independent Cancer Trials
The questions the market won't pay to answer are the ones patients need most.
Mark
What's the practical difference between an academic trial and an industry trial? Aren't they both just testing treatments?
Mimi
The goal is different. Industry trials are built to answer one question: does this drug work well enough to get approved? Academic trials ask what happens after approval — who benefits, at what dose, combined with what, and at what cost to quality of life.
Mark
So industry trials aren't enough on their own?
Mimi
They get treatments to market. But they don't tell you how to use them once they're there. That's the gap academic research fills, and it's a gap the market has no particular reason to close.
Mark
Why does it matter that the coalition spans six continents?
Mimi
Because the evidence base for cancer care has historically been built in wealthy countries and then applied everywhere. If the people designing trials don't include voices from Africa or South America, the science reflects that absence.
Mark
What's actually threatening academic trials right now?
Mimi
Three things, according to the people in that room: regulations that have become expensive and slow to navigate, public funding that hasn't grown with the need, and no real infrastructure for running coordinated trials across borders.
Mark
Is this commission the first attempt to address that?
Mimi
No — the WHO has its own Global Clinical Trials Forum working on similar problems. The EORTC commission is explicitly trying to align with those efforts rather than compete with them.
Mark
What would success look like?
Mimi
New collaboration models that let academic researchers run international trials without surrendering control to commercial partners or drowning in regulatory overhead. The commission is supposed to produce specific, workable proposals — not just a diagnosis of the problem.
Mark
And if nothing changes?
Mimi
Academic cancer research becomes something only the best-funded institutions in the richest countries can do. The questions that matter most to patients — how to live well after treatment, not just survive it — go unanswered.
The Pulse
- Academic cancer trials — the ones asking how to reduce suffering and extend quality of life, not just win drug approvals — are losing ground to regulatory complexity, shrinking public budgets, and fragmented international infrastructure.
- Without coordinated global support, this kind of research risks becoming the exclusive domain of wealthy, well-resourced institutions, narrowing both the science and the populations it serves.
- A 35-member coalition spanning Africa, Asia, Oceania, Europe, the Middle East, and the Americas has formally launched a Lancet Oncology Commission to diagnose the crisis and move toward concrete solutions.
- The commission is designed to deliver actionable recommendations — new collaboration models, funding mechanisms, and regulatory pathways — while aligning with existing global efforts rather than duplicating them.
- Its work is just beginning, but the argument it is making is already clear: independent academic cancer research is not a specialist concern, it is a structural requirement for any healthcare system serious about equity and outcomes.
In the spring of 2026, thirty-five oncologists, researchers, and patient advocates from six continents formalized a shared conviction: that the cancer research most essential to patients — not to markets — is quietly being eroded. Coordinated by the EORTC and announced in The Lancet Oncology, their new commission exists to name the forces threatening independent academic trials and to propose the structural changes needed to preserve them. At stake is not merely a funding dispute, but the question of whose lives the evidence of medicine is built around.
In March 2026, thirty-five oncologists, researchers, and patient representatives from every inhabited continent gathered around a shared concern: that the cancer research most directly useful to patients is quietly losing ground. From that meeting emerged a formal commission, announced in The Lancet Oncology, dedicated to understanding what is at stake — and what can be done.
The distinction driving the effort rarely makes headlines but profoundly shapes care. Industry trials exist to win regulatory approval for new drugs. Academic trials ask harder, less profitable questions: which patients benefit most from existing treatments? How can side effects be reduced? What combination of therapies produces the best long-term quality of life? These are the questions that govern day-to-day cancer care, and they are questions commercial sponsors have little financial incentive to fund.
The coalition is coordinated by the EORTC, whose chief executive Denis Lacombe described independent academic trials plainly as a public good — evidence that optimizes care beyond what the market will pay for. EORTC president Winette van der Graaf framed the commission's central challenge: finding new models of global collaboration that preserve academic independence while enabling efficient, high-quality international trials.
Three concrete pressures were named at the March meeting: regulatory systems grown too complex and costly to navigate, public funding that has not kept pace with scientific ambition, and a lack of coordinated cross-border infrastructure. Individually, each is manageable. Together, they threaten to concentrate independent cancer research in a shrinking number of wealthy institutions — and the science they produce will reflect that narrowing.
The equity dimension is significant. Trials concentrated in Western Europe or North America generate evidence shaped by those populations. A genuinely global coalition produces science with broader applicability and, in principle, helps close the gap in cancer outcomes between rich and poor countries.
The commission's recommendations are still to come. What March established is the argument: that independent academic cancer research is not a niche concern but a structural requirement for any healthcare system serious about improving outcomes for all its patients.
In March 2026, thirty-five people gathered — oncologists, researchers, and patient representatives drawn from Africa, Asia, Oceania, Europe, the Middle East, and both Americas — with a shared concern: that the kind of cancer research most directly useful to patients is quietly losing ground. Out of that meeting came a formal commission, announced in The Lancet Oncology, dedicated to understanding what is at stake and what can be done about it.
The distinction at the heart of this effort is one that rarely makes headlines but shapes what treatments patients actually receive. Industry-led clinical trials exist to win regulatory approval for new drugs. Academic trials ask different questions: which patients benefit most from treatments already available? How can side effects be reduced? What combination of therapies produces the best long-term quality of life? These are the questions that determine how cancer care is practiced day to day, and they are questions that commercial sponsors have little financial incentive to fund.
The coalition behind the new commission is coordinated by the European Organisation for Research and Treatment of Cancer, known as the EORTC. Denis Lacombe, the organization's chief executive, put the argument plainly: independent academic cancer trials are a public good. They produce evidence that optimizes care beyond what the market will pay for, and they are foundational to healthcare systems where research is woven into routine treatment rather than siloed in specialized centers.
Winette van der Graaf, the EORTC's president, captured the mood of the March gathering in a single sentence: the participants agreed they need new models of global collaboration that preserve academic independence while still enabling efficient, high-quality international trials. That tension — between independence and scale, between local relevance and global reach — is the central problem the commission is being asked to solve.
The challenges are not abstract. Participants at the March meeting named three concrete pressures bearing down on academic research: regulatory systems that have grown more complex and costly to navigate, public funding that has not kept pace with the ambition of the science, and a lack of coordinated infrastructure for running trials across national borders. Each of these problems is manageable in isolation; together, they threaten to make independent cancer research the province of a shrinking number of well-resourced institutions in wealthy countries.
The equity dimension is significant. When academic trials are concentrated in a handful of countries, the evidence they generate reflects the populations enrolled in them. Treatments optimized for patients in Western Europe or North America may not translate cleanly to patients elsewhere. A genuinely global coalition — one that includes investigators and patient voices from every inhabited continent — produces science with broader applicability and, in principle, narrows the gap in cancer outcomes between rich and poor countries.
The new Lancet Oncology Commission is designed to move from diagnosis to prescription. Its stated aim is to deliver actionable recommendations: concrete proposals for collaboration models, funding mechanisms, and regulatory approaches that would allow academic cancer trials to continue operating at the scale the problem demands. The initiative is also positioned to align with existing international efforts, including the WHO Global Clinical Trials Forum, rather than duplicate them.
The commission's work is just beginning, and its recommendations are still to come. What the March meeting established is the argument — that independent academic cancer research is not a niche concern for specialists but a structural requirement for any healthcare system serious about improving outcomes for all its patients. Whether the commission can translate that argument into durable change is the question worth watching.
Notable Quotes
Independent academic cancer clinical trials are a public good — they generate the evidence needed to optimize cancer care beyond commercial priorities.— Denis Lacombe, CEO of the EORTC
We all agreed we need new models of global collaboration that preserve academic independence while enabling efficient, high-quality international trials.— Winette van der Graaf, President of the EORTC
Want the full story?
Read the original at News-Medical ↗
Health & Medicine